John M. Rothman
Corporate Officer/Principal bei TYME TECHNOLOGIES, INC.
Profil
John M.
Rothman is currently the Executive Vice President-Product Development at Tyme Technologies, Inc. He previously worked as the EVP-Clinical & Scientific Operations at Advaxis, Inc. from 2011 to 2013.
He also worked as the Chief Scientific Officer at Race Oncology Ltd.
Dr. Rothman earned a doctorate degree from Tulane University School of Medicine.
Aktive Positionen von John M. Rothman
| Unternehmen | Position | Beginn |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Corporate Officer/Principal | 19.08.2020 |
Ehemalige bekannte Positionen von John M. Rothman
| Unternehmen | Position | Ende |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | 01.10.2019 |
| AYALA PHARMACEUTICALS, INC. | Chief Operating Officer | 09.12.2011 |
Ausbildung von John M. Rothman
| Tulane University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RACE ONCOLOGY LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
